Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/66326
FUNDING FOR RESEARCH ON CRYPTOCOCCAL DISEASE: AN ANALYSIS BASED ON THE G-FNDER REPORT
Affilliation
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil / Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Carlos Chagas. Curitiba, PR, Brasil / Universidade Federal do Rio de Janeiro. Centro de Ciências da Saúde. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
Abstract
Members of the genus Cryptococcus are the causative agents of cryptococcal meningitis, a disease mainly associated with HIV-induced immunosuppression. Patients with cryptococcal meningitis are at a serious risk of death. Most patients sufering from cryptococcosis belong to neglected populations. With reduced support for research, new therapies are unlikely to emerge. In this essay, we used the Policy Cures/G-fnder platform as a reference database for funding research on cryptococcal disease. Funding for cryptococcal research started being tracked by G-fnder in 2013 and has continued to appear in the annual reports ever since. In total, 15 institutions were reported as major funders for research on cryptococcal disease over the years. The US National Institutes of Health (NIH) was the main funder, followed by the UK’s Wellcome Trust. The annual analysis suggested slow yearly growth in funding from 2013 to 2021. The development of new tools to prevent and fght cryptococcal disease is urgent but requires improved funding.
Share